Table of Contents
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - November 27, 2017 Category: Nuclear Medicine Source Type: research
Expanding LogP: Present Possibilities
Due to the high candidate exclusion rate during a drug development process, an early prediction of the pharmacokinetic behavior would be needed. Accordingly, high performance bioaffinity chromatography (HPBAC) approaches are growing in popularity, however, there is a lack of knowledge and no consensus about the relation between HPBAC measurements, in vivo distribution and blood brain barrier (BBB) penetration behavior. With respect to radiotracers, there is almost no reference data available for plasma protein binding (PPB), permeability (Pm) and the membrane coefficient (KIAM). (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - November 27, 2017 Category: Nuclear Medicine Authors: Chrysoula Vraka, Sanja Mijailovic, Vanessa Fr öhlich, Markus Zeilinger, Eva-Maria Klebermass, Wolfgang Wadsak, Karl-Heinz Wagner, Marcus Hacker, Markus Mitterhauser Source Type: research
Speed matters to raise molar radioactivity: Fast HPLC shortens the quality control of C-11 PET-tracers
The decision whether an in-house produced short-lived radiopharmaceutical can be applied in-vivo is based on (1) the fulfilment of all quality criteria; (2) the availability of enough radioactivity for subsequent imaging; and (3) a molar activity (MA) above the set limits to guarantee safe administration without competing occupancy of the non-radioactive compound; and (4) an activity concentration, which is high enough for the application in certain preclinical studies. Hence, time reduction can be of major importance to increase final product yields, MA and activity concentrations. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - November 20, 2017 Category: Nuclear Medicine Authors: Lukas Nics, Britta Steiner, Eva-Maria Klebermass, Cecile Philippe, Markus Mitterhauser, Marcus Hacker, Wolfgang Wadsak Source Type: research
89Zr for antibody labeling and in vivo studies – a comparison between liquid and solid target production
Zirconium-89 (89Zr, t1/2 = 78.4 h) liquid target (LT) production offers an approach to introduce this positron-emitting isotope to cyclotron centres without the need for a separate solid target (ST) production set up. We compared the production, purification, and antibody radiolabeling yields of 89Zr-(LT) and 89Zr-(ST), and assessed the feasibility of 89Zr-(LT) for preclinical PET/CT. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - November 16, 2017 Category: Nuclear Medicine Authors: Gemma M. Dias, Caterina F. Ramogida, Julie Rousseau, Nicholas A. Zacchia, Cornelia Hoehr, Paul Schaffer, Kuo-Shyan Lin, Fran çois Bénard Source Type: research
Synthesis, in vitro and in vivo evaluation of 18F-fluoronorimatinib as radiotracer for Imatinib-sensitive gastrointestinal stromal tumors
Gastrointestinal stromal tumors (GIST) have a wide range of mutations, but can mostly be treated with Imatinib, until eventually resistance towards this tyrosine kinase inhibitor is acquired. Early and non-invasive determination of the sensitivity of the tumor and its metastases towards Imatinib by positron emission tomography (PET) would be beneficial for therapy planning and monitoring. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - November 16, 2017 Category: Nuclear Medicine Authors: Martin Prause, Sabrina Niedermoser, Carmen W ängler, Clemens Decristoforo, Uwe Seibold, Stephanie Riester, Takahiro Taguchi, Ralf Schirrmacher, Gert Fricker, Björn Wängler Source Type: research
Synthesis and evaluation of 99mTc/Re-tricarbonyl complexes of the triphenylphosphonium cation for mitochondrial targeting
Introduction: Lipophilic delocalized cations accumulate in tumor cell mitochondria due to their higher transmembrane potential. In this work, this strategy was adopted for the development of 99mTc tumor-targeted imaging agents.Methods: Two tridentate ligands containing the triphenylphosphonium cation, L1 (S-cysteinyl) and L2 (N-iminodiacetate) as well as the respective 99mTc/ReL1 and 99mTc/ReL2 tricarbonyl complexes were synthesized. The effect of the ligands and the Re complexes on cell growth in U-87 MG glioblastoma cells was assessed. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - November 13, 2017 Category: Nuclear Medicine Authors: Georgios Paparidis, Melpomeni Akrivou, Vicky Tsachouridou, Antonio Shegani, Ioannis S. Vizirianakis, Ioannis Pirmettis, Minas S. Papadopoulos, Dionysia Papagiannopoulou Source Type: research
Cyclotron production of 99mTc
Intensive efforts were undertaken during the last few decades for the separation of cyclotron-produced 99mTc from 99Mo and new papers have been published on this topic since the last review [1]. In the future the cyclotron-based methods can replace reactor-based technology in producing this medical radioisotope and the nuclear reaction 100Mo(p,2n)99mTc appears to be the most worthwhile approach. New ways of producing of 99mTc require efficient separation methods. Several strategies for separation of 99mTc from 99Mo have been already developed. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - November 9, 2017 Category: Nuclear Medicine Authors: Magdalena Gumiela Source Type: research
Alkaline degradation of lyophilized DMSA prior to labeling with 99mTc: Identification and development of the degradation pathway by HPLC and MS
In this study, the DMSA kit was subjected to forced degradation under hydrolysis conditions as prescribed by the International Conference on Harmonization (ICH) guideline Q1A. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - November 9, 2017 Category: Nuclear Medicine Authors: Erika V. Almeida, Samuel L. De Brito Source Type: research
Separation methods of cyclotron-produced 99mTc
Intensive efforts were undertaken during the last few decades for the separation of cyclotron-produced 99mTc from 99Mo and new papers have been published on this topic since the last review [1]. In the future the cyclotron-based methods can replace reactor-based technology in producing this medical radioisotope and the nuclear reaction 100Mo(p,2n)99mTc appears to be the most worthwhile approach. New ways of producing of 99mTc requires efficient separation methods. Several strategies for separation of 99mTc from 99Mo have been already developed. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - November 9, 2017 Category: Nuclear Medicine Authors: Gumiela Magdalena Source Type: research
Editorial Board
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - November 1, 2017 Category: Nuclear Medicine Source Type: research
Table of Contents
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - November 1, 2017 Category: Nuclear Medicine Source Type: research
18F-labeled norepinephrine transporter tracer [18F]NS12137: radiosynthesis and preclinical evaluation
Several psychiatric and neurodegenerative diseases are associated with malfunction of brain norepinephrine transporter (NET). However, current clinical evaluations of NET function are limited by the lack of sufficiently sensitive methods of detection. To this end, we have synthesized exo-3-[(6-[18F]fluoro-2-pyridyl)oxy]-8-azabicyclo[3.2.1]-octane ([18F]NS12137) as a radiotracer for positron emission tomography (PET) and have demonstrated that it is highly specific for in vivo detection of NET-rich regions of rat brain tissue. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - October 25, 2017 Category: Nuclear Medicine Authors: Anna K. Kirjavainen, Sarita Forsback, Francisco R. L ópez-Picón, Päivi Marjamäki, Jatta Takkinen, Merja Haaparanta-Solin, Dan Peters, Olof Solin Source Type: research
Evaluation of a novel GRPR antagonist for prostate cancer PET imaging: [64Cu]-DOTHA2-PEG-RM26
Gastrin releasing peptide receptors (GRPRs) are significantly over-expressed on a large proportion of prostate cancers making them prime candidates for receptor-mediated nuclear imaging by PET. Recently, we synthesized a novel bifunctional chelator (BFC) bearing hydroxamic acid arms (DOTHA2). Here we investigated the potential of a novel DOTHA2-conjugated, 64Cu-radiolabeled GRPR peptide antagonist, [D-Phe6-Sta13-Leu14-NH2]bombesin(6-14) (DOTHA2-PEG-RM26) to visualize prostate tumors by PET imaging. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - October 23, 2017 Category: Nuclear Medicine Authors: Nematallah Mansour, Michel Paquette, Samia Ait-Mohand, V éronique Dumulon-Perreault, Brigitte Guérin Source Type: research
Development of two Fluorine-18 labeled PET radioligands targeting PDE10A and in vivo PET evaluation in nonhuman primates
Phosphodiesterase 10A (PDE10A) is a member of the PDE enzyme family that degrades cyclic adenosine and guanosine monophosphates (cAMP and cGMP). Based on the successful development of [11C]T-773 as PDE10A positron emission tomography (PET) radioligand, in this study our aim was to develop and evaluate fluorine-18 analogs of [11C]T-773. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - October 23, 2017 Category: Nuclear Medicine Authors: Vladimir Stepanov, Akihiro Takano, Ryuji Nakao, Nahid Amini, Shotaro Miura, Tomoaki Hasui, Haruhide Kimura, Takahiko Taniguchi, Christer Halldin Source Type: research
The past, present, and the promise of the future of Nuclear Medicine and Biology
The Past and Present. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - October 11, 2017 Category: Nuclear Medicine Authors: W.C. Eckelman, A.D. Windhorst, C. O ’Hara Source Type: research
